Drug interaction study: bosentan may change zongertinib levels

NCT ID NCT07649941

Not yet recruiting Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 19, 2026

Summary

This early-stage trial will test whether taking bosentan (a drug for blood pressure) changes how the body processes zongertinib (an experimental cancer drug). Sixteen healthy men will receive zongertinib alone and then with bosentan to compare drug levels. The study is not intended to treat any disease, but to gather safety and dosing information for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Humanpharmakologisches Zentrum Biberach

Biberach, 88397, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bosentan and zongertinib

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY